TP53 and colorectal carcinoma: Of note, regorafenib effectively inhibited the growth of TP53 knockout cells (HCT116 p53−/−), which has been generally viewed as a CRC cell line resistant to chemotherapy, suggesting that this agent exerts its growth inhibitory effects on CRC growth in a p53-independent manner.